enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.
Sector:
Commercial Services
Industry:
Miscellaneous Commercial Services
Employees:
82
Frequently Asked Questions
What is Market Cap of enGene Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. enGene Therapeutics Inc. market cap is $482.32M.
What is the 52-week high for enGene Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. enGene Therapeutics Inc. 52 week high is $12.25 as of April 12, 2026.
What is the 52-week low for enGene Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. enGene Therapeutics Inc. 52 week low is $2.65 as of April 12, 2026.
What is enGene Therapeutics Inc. stock price today?
enGene Therapeutics Inc. stock price today is $7.20.
What was enGene Therapeutics Inc. stock price yesterday?
enGene Therapeutics Inc. stock price yesterday was $7.27.
What is the PE ratio of enGene Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. enGene Therapeutics Inc.'s P/E ratio is -3.19.
What is the Price-to-Book ratio of enGene Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. enGene Therapeutics Inc. P/B ratio is 1.7131.
What is the 50-day moving average of enGene Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. enGene Therapeutics Inc. 50-day moving average is $8.46.
How many employees does enGene Therapeutics Inc. have?